CASI — Stock activity · TradeandTell
CASI CASI $0.21 -$0.59 (-74.06%) prev close
Held by
0
portfolios on TandT
Avg position size
—
of holders' portfolios
52-week range
$0.21 – $3.09
0% from low
Price Valuation Financials Segments
Held by traders on TradeandTell No one on the platform currently holds CASI.
Super investors & insiders Institutions holding (13F)
No tracked institution reports a position in CASI as of their last filing.
Insider activity (SEC Form 4)
Stock splits Execution date Ratio 2022-06-02 1-for-10reverse
Recent trades on TradeandTell No one on the platform has traded CASI yet.
Report a bug Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Analyst estimates (consensus) Year Est. revenue Growth Est. EPS EPS range Fwd P/E # Analysts 2026 $70M +421.5% $-1.41 $-1.41–$-1.41 — 1 2027 $89M +27.2% $-1.39 $-1.39–$-1.39 — 1 2028 $108M +20.8% $-1.37 $-1.37–$-1.37 — 1 2029 $11M -89.7% $-0.97 $-0.97–$-0.97 — 1
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Earnings surprises Beat consensus in 2 of the last 8 reported quarters
Reported Est. EPS Actual Surprise 2025-11-14 $-0.40 $-0.67 -67.5% 2025-08-29 $-0.47 $-0.86 -83.0% 2025-05-16 $-0.61 $-0.69 -13.1% 2025-03-31 $-0.60 $-0.79 -31.7% 2024-11-15 $-0.62 $-0.55 +11.3% 2024-08-16 $-0.63 $-0.52 +17.5% 2024-05-14 $-0.05 $-0.71 -1320.0% 2024-03-28 $-0.24
Peer comparison Symbol Price Today Mkt cap P/E CASI CASI Pharmaceuticals, Inc. $0.15 +3.08% $2M — ALLR Allarity Therapeutics, Inc. $1.40 +0.36% $22M — CING Cingulate Inc. $5.02 -3.56% $68M — CLSD Clearside Biomedical, Inc. $0.41 +0.00% $2M — CRIS Curis, Inc. $1.59 -4.49%
ENTO Entero Therapeutics, Inc. $2.85 -5.00% $14M —
KAPA Kairos Pharma, Ltd. $0.35 -1.18% $8M —
Source: Financial Modeling Prep · peers by sector/industry
$CASI chatter on StockTwits $CASI $CASIF at some point the market makers will run this to get the intitutional investors out Right now about 32% of the 19 million shares outstanding are held by institutions.
View on StockTwits ↗ $CASI $CASIF
Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
View on StockTwits ↗ Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
